Saturday 17 October 2026
Export AVR’s income statement to Excel — free account
Anteris Technologies Global Corp.
AVR Healthcare Medical Instruments & Supplies
Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024. In the quarter to June 2026, revenue grew 63.3%, EPS grew 48.3%, free cash flow fell 6.84% and total debt rose 8.15%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.05
0.31
−4.87%
Follow AVR
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 5.10 | 2.34 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 6.00 | 8.79 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 138 | 136 | 174 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.02 | 0.02 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 3 | 3 | 2 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 32.07 | 46.84 | 70.26 | |||||
| EBT | — | — | — | — | — | — | — | (47) | (76) | (94) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (1,709.84) | (2,810.47) | (4,925.51) | |||||
| Net income | — | — | — | — | — | — | — | (47) | (76) | (94) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.18 | 0.13 | 0.05 | ||||
| Earnings | — | — | — | — | — | — | — | (2.95) | (3.68) | (2.55) | |||||
| Cash flow | — | — | — | — | — | — | — | (2.22) | (3.02) | (2.11) | |||||
| Capex | — | — | — | — | — | — | — | (0.15) | (0.11) | (0.05) | |||||
| Free cash flow | — | — | — | — | — | — | — | (2.37) | (3.14) | (2.16) | |||||
| Book value | — | — | — | — | — | — | — | 1.21 | 3.10 | (0.01) | |||||
| Shares, m | — | — | — | — | — | — | — | 16 | 20 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 41.81 | 96.28 | |||||
| P/B | — | — | — | — | — | — | — | 6.08 | 1.80 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 15.75 | 89.73 | |||||
| EV/FCF | — | — | — | — | — | — | — | (1.19) | (0.67) | (2.15) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (35) | (61) | (78) | ||||
| Capex | — | — | — | — | — | — | — | (2) | (2) | (2) | |||||
| Free cash flow | — | — | — | — | — | — | — | (37) | (64) | (80) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 15 | 58 | (6) | ||||
| Total debt | — | — | — | — | — | — | — | 1 | 0 | 0 | |||||
| Net debt | — | — | — | — | — | — | — | (20) | (70) | (13) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 19 | 63 | 0 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (137.18) | (181.58) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (187.03) | (301.60) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Anteris Technologies Global Corp. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AZTA Azenta, Inc. | $1.6B | — (loss-making) | — (loss-making) | +12.04% (above 0%: growing) | n/m | −134.69% (below 0%: shrinking) | 44.89% | (2.59%) | Compare |
| STAA STAAR Surgical Company | $1.1B | 304× | 103× | +111.04% (above 0%: growing) | n/m | +166.10% (above 0%: growing) | 74.55% | 10.80% | Compare |
| AVR Anteris Technologies Global Corp. | $619.8M | — (loss-making) | — | +63.27% (above 0%: growing) | n/m | −6.84% (below 0%: shrinking) | 76.91% | (3,072.05%) | |
| ANGO AngioDynamics, Inc. | $487.0M | — (loss-making) | — (loss-making) | +6.87% (above 0%: growing) | n/m | +5.62% (above 0%: growing) | 59.37% | (9.02%) | Compare |
| NNNN Anbio Biotechnology | $474.8M | — | — | — | — | — | — | — | Compare |
| EMBC Embecta Corp. | $365.5M | 4.2× | 3.8× | −8.05% (below 0%: shrinking) | −53.85% (below 0%: shrinking) | −49.63% (below 0%: shrinking) | 56.42% | 17.92% | Compare |
| ZJYL Jin Medical International Ltd. | $340.9M | — | — | — | — | −8,074.17% (below 0%: shrinking) | 34.44% | 0.00% | Compare |
| SMTI Sanara MedTech Inc. | $322.4M | — (loss-making) | 125× | +9.04% (above 0%: growing) | n/m | +131.28% (above 0%: growing) | 92.96% | 6.33% | Compare |
| OSUR OraSure Technologies, Inc. | $262.8M | — (loss-making) | — (loss-making) | −1.93% (below 0%: shrinking) | n/m | −1.40% (below 0%: shrinking) | 43.46% | 17.76% | Compare |
| Median of peers | $420.2M | — | 103× | +7.96% | — | −1.40% | 56.42% | 6.33% |
Anteris Technologies Global Corp. (AVR) key facts
- Concern: Anteris Technologies Global Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 million, down 29.2% from fiscal 2024.
- Anteris Technologies Global Corp. (AVR) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, AVR traded at $6.05, a market capitalization of $619.8 million.
- Return on equity was −301.6% and debt-to-equity 0.00.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −31.49 (distress zone) for fiscal 2025.